About
In-Licensing & Developing Oncology Assets for Sale
Areas of Focus
Categories
Biologics & BiopharmaceuticalSmall Molecule PharmaceuticalBoston & New England
Team (2)
Clinical Trials (10)
View allTotal Trials
10
As Lead Sponsor
10
As Collaborator
0
Total Enrollment
1,101
By Phase
PHASE1: 8PHASE1/PHASE2: 2
By Status
RECRUITING: 6ACTIVE_NOT_RECRUITING: 3TERMINATED: 1
Clinical Trials Pipeline10 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
Today
Hover over trial bars to see details
Recent Trials
NCT07041099Lead Sponsor
A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Sjogren's Disease
PHASE1Recruiting
36 participants
Started: Sep 15, 2025 · Completed: Mar 15, 2029
NCT06994143Lead Sponsor
A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Rheumatoid Arthritis
PHASE1Recruiting
37 participants
Started: May 19, 2025 · Completed: Dec 30, 2028
NCT06613360Lead Sponsor
A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus
PHASE1Recruiting
24 participants
Started: Jan 21, 2025 · Completed: Dec 31, 2027
NCT06381141Lead Sponsor
A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma
PHASE1Active, not recruiting
30 participants
Started: Sep 3, 2024 · Completed: Mar 31, 2027
NCT06035744Lead Sponsor
CLN-617 Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
PHASE1Recruiting
86 participants
Started: Dec 12, 2023 · Completed: Jun 30, 2028
Locations (1)
Headquarters
Cambridge, MA, United States
Map
Loading map...